Crowdonomics
All companies
PLASMOLOGY4 logo

PLASMOLOGY4

Operating

Plasmology4, Inc.

Healthcare · Technology · Scottsdale, AZ · Founded 2010

Revolutionary technology for healthcare

Post-money valuation
$137.5M
As of Oct 2024 · from Plasmology4 Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$728,771
Across 1 round since 2024
Latest share price
$1.17
Plasmology4 Common Stock 1 offering price

Financials

FY2022–FY2025 · from SEC filings · hover any figure for its source
$0
−$10.4M
2022
$0
−$4.2M
2023
$0
−$7.0M
2024
$0
−$4.4M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
Net income
-$10,364,267
-$4,228,434
-$6,999,368
-$4,359,243
Taxes paid
$0
$0
$27
$56
Balance sheet
Cash
$1,171,233
$466,085
$16,676
$12,162,189
Accounts receivable
$0
$0
$0
$0
Total assets
$1,902,460
$1,250,330
$634,623
$12,483,429
Short-term debt
$4,758,917
$1,000,000
$1,492,220
$1,491,758
Long-term debt
$336,923
$0
$0
$276,151
Total liabilities
$5,095,840
$1,000,000
$1,492,220
$1,767,909
Other
Headcount
7
7
6

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Post-money = pre-money + amount raised · caps marked
$137.5M
post-money
Plasmology4 Common Stock 1

A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.

Fundraising history

Plasmology4 Common Stock 1ClosedReg CF · Common Equity · via StartEngine
Raised $728.8K / $1.2MInvestors 215Post-money $137.5M

Team

14 people
Robert Hummel, MBA
Chief Executive Officer

Seasoned executive with 30+ years of experience in the medical tech/device industry. Extensive experience in the spine surgery, orthopedic surgery and wound care market segments. Named inventor of 20+ patents and patent applications. Robert will be providing Form C sign-off as the Company's Principal Accounting Officer.

Robert Hummel
CEO, Director, Principal Accounting Officer
Greg Watson
Chief Innovation Officer & Chief Technology Officer

30+ years of experience with invention development and the inventor of the initial form of the Plaz4 technology. Inventor of 25+ patents in the field of cold plasma.

Marc Jacofsky, PhD
Chief Scientific Officer

Experienced biomedical researcher and inventor. Managed over 50 clinical trials with over 25 peer-reviewed publications. Issued over 30 patents as named inventor.

Rich John, MBA
Vice President of Information Technology; Accounting and Shareholder Relations

Experienced IT system and software architect, with expertise in business process design, operations, accounting, and ERP systems.

Emilia Kulaga, PhD
Senior Director of Research

Experienced biomedical researcher with expertise in non-thermal plasma research, startup product development and regulatory strategies. Recipient of a prestigious IMPRS fellowship from the Max Planck Institute in Germany.

Michel Yoon
Director of Engineering

15+ years of experience designing medical devices, with several devices currently on market. 8 issued patents related to medical devices.

Courtney Versage
Laboratory Manager, Microbiology

A skilled laboratory manager specializing in microbiology, she has dedicated her career to advancing the Plaz4 technology platform, with a strong focus on non-thermal plasma research.

David Jacofsky, MD
Scientific Advisory Board Member & Chairman of Board of Directors

Founder and Chairman of Board of Directors of The CORE Institute and Healthcare Outcomes Performance Company (HOPCo). Board certified by the American Academy of Orthopedic Surgeons. International speaker and authority on complex adult joint reconstruction, orthopedic oncology, and orthopedic soft tissue infections.

Show 5 more people
Roy Sanders, MD
Scientific Advisory Board Member

Founder, President and Chairman of the Board of the Florida Orthopedic Institute, Tampa, FL. Has authored over 100 articles and abstracts on orthopedic trauma, published several textbooks on orthopedic trauma, and is presently the Editor-in-Chief of the Journal of Orthopedic Trauma, the leading international journal in the field.

Steven Moran, MD
Scientific Advisory Board Member

Professor of Surgery and Orthopedic Surgery at the Mayo Clinic in Rochester, MN. Chair of the Division of Plastic Surgery and Reconstructive Surgery and the surgical director of hand transplantation at Mayo Clinic's Essam and Dalal Obaid Center for Reconstructive Transplant Surgery.

James Lawson, Jr.
Director
Ronald Robinson
Director
Stephen Brigido, Jr.
Director

Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFewer than 300 holders of record

Filed 2 of 2 annual reports (FY2024–FY2025)

215 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form C-ARMay 5, 20260001488790-26-000005
    EDGAR
  • Form C-ARApr 28, 20250001665160-25-000780
    EDGAR
  • Form C-UApr 1, 20250001665160-25-000506
    EDGAR
  • Form C/AFeb 14, 20250001665160-25-000254
    EDGAR
  • Form C/AJan 13, 20250001665160-25-000047
    EDGAR
  • Form COct 21, 20240001665160-24-001425
    EDGAR
  • Form DDec 15, 20160001596771-16-000172
    EDGAR
  • Form DApr 5, 20160001488790-16-000006
    EDGAR
Source: ManualCIK 0001488790NVShare price $1.17

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.